Dublin, Oct. 14, 2024 (GLOBE NEWSWIRE) -- The "Complement 3 Glomerulopathy - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Complement 3 Glomerulopathy - Pipeline Insight, 2024" report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Complement 3 Glomerulopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Complement 3 Glomerulopathy pipeline landscape is provided which includes the disease overview and Complement 3 Glomerulopathy treatment guidelines. The assessment part of the report embraces, in depth Complement 3 Glomerulopathy commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Complement 3 Glomerulopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Complement 3 Glomerulopathy R&D. The therapies under development are focused on novel approaches to treat/improve Complement 3 Glomerulopathy.
Complement 3 Glomerulopathy Emerging Drugs Chapters
This segment of the Complement 3 Glomerulopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Complement 3 Glomerulopathy Emerging Drugs
Pegcetacoplan: Apellis Pharmaceuticals, Inc.
Pegcetacoplan (Empaveli) is an immunosuppressant that is given by subcutaneous (under the skin) infusion. Pegcetacoplan, a targeted C3 and C3b inhibitor, may mitigate complement-mediated kidney damage in C3G and other glomerular diseases in which complement may have a pathogenic role. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Complement 3 Glomerulopathy.
Complement 3 Glomerulopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Complement 3 Glomerulopathy therapeutic drugs key players involved in developing key drugs.
Key Questions
- How many companies are developing Complement 3 Glomerulopathy drugs?
- How many Complement 3 Glomerulopathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Complement 3 Glomerulopathy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Complement 3 Glomerulopathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Complement 3 Glomerulopathy and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Apellis Pharmaceuticals, Inc.
- Kira Pharmacenticals
Key Products
- Pegcetacoplan
- KP104
Complement 3 Glomerulopathy Therapeutic Assessment
Major Players in Complement 3 Glomerulopathy
- There are approx. 3+ key companies which are developing the therapies for Complement 3 Glomerulopathy. The companies which have their Complement 3 Glomerulopathy drug candidates in the most advanced stage, i.e. Phase III include, Apellis Pharmaceuticals, Inc.
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Complement 3 Glomerulopathy Report Insights
- Complement 3 Glomerulopathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Complement 3 Glomerulopathy Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/8lglm9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
